Abstract:Photodynamic therapy (PDT) as a non-invasive anticancer modality has received increasing attention due to its advantages of noninvasiveness, high temporospatial selectivity, simple and controllable operation, etc. . PDT mainly relies on the generation of toxic reactive oxygen species (ROS) by photosensitizers (PSs) under the light irradiation to cause cancer cell apoptosis and death. However, solid tumors usually exhibit an inherent hypoxic microenvironment, which greatly limits the PDT efficacy of these high oxygen-dependent conventional type II PSs. Therefore, it is of great importance to design and develop efficient type I PSs that are less oxygen-dependent for the treatment of hypoxic tumors. Herein, a new strategy for the preparation of efficient type I PSs by introducing the photoinduced electron transfer (PET) mechanism is reported. DR-NO2 2 is obtained by introducing 4-nitrobenzyl to (Z)-2-(5-(4-(diethylamino)-2-hydroxybenzylidene)-4-oxo-3-phenylthiazolidin-2- Z )-2-(5-(4-(diethylamino)-2-hydroxybenzylidene)-4-oxo-3-phenylthiazolidin-2- ylidene)malononitrile (DR-OH) with aggregation-induced emission (AIE) feature. The AIE feature ensures their high ROS generation efficiency in aggregate, and the PET process leads to fluorescence quenching of DR-NO2 2 to promote triplet state formation, which also promotes intramolecular charge separation and electron transfer that is conducive for type I ROS particularly superoxide radicals generation. In addition, DR-NO2 2 nanoparticles are prepared by nanoprecipitation to possess nanoscaled sizes, high cancer cell uptake, and excellent type I ROS generation ability, which results in an excellent performance in PDT ablation of MCF-7 cancer cells. This PET strategy for the development of type I PSs possesses great potential for PDT applications against hypoxic tumors.

Type I Photosensitizer Targeting G‐Quadruplex RNA Elicits Augmented Immunity for Cancer Ablation

Promising G-Quadruplex-Targeted Dibenzoquinoxaline Type-1 Photosensitizer Triggers DNA Damage in Triple-Negative Breast Cancer Cells

Unusual Electron Donor-Acceptor Sequenced NIR AIEgen for Highly Efficient Mitochondria-Targeted Cancer Cell Photodynamic Therapy.

Slight Modification of a G-quadruplex-targeted Quinoxaline May Boost Type-1 Photodynamic Therapy for Triple-Negative Breast Cancer

Photodynamic Therapy with Tumor Cell Discrimination through RNA-Targeting Ability of Photosensitizer

Type I Photosensitizer Based on AIE Chromophore Tricyano-Methylene-pyridine for Photodynamic Therapy

Efficient type I and type II ROS generated aggregation-induced emission photosensitizer for mitochondria targeted photodynamic therapy

RNA-Activatable Near-Infrared Photosensitizer for Cancer Therapy

Type I Photosensitization with Strong Hydroxyl Radical Generation in NIR Dye Boosted by Vigorous Intramolecular Motions for Synergistic Therapy

A Photosensitizer Discretely Loaded Nanoaggregate with Robust Photodynamic Effect for Local Treatment Triggers Systemic Antitumor Responses

Construction of Type I Aggregation-Induced Emission Photosensitizers for Photodynamic Therapy Via Photoinduced Electron Transfer Mechanism

An Acceptor-Shielding Strategy of Photosensitizers for Enhancing the Generation Efficiency of Type I Reactive Oxygen Species and the Related Photodynamic Immunotherapy

Type I photodynamic therapy with a self-degradable conjugated polyelectrolyte in combination with CpG adjuvant for cancer immunotherapy

Self-assembly-integrated tumor targeting and electron transfer programming towards boosting tumor type I photodynamic therapy

A Highly Efficient and Photostable Photosensitizer with Near-Infrared Aggregation-Induced Emission for Image-Guided Photodynamic Anticancer Therapy

Activatable Type I Photosensitizer with Quenched Photosensitization Pre and Post Photodynamic Therapy.

Type I AIE photosensitizers: Mechanism and application

Toward Type I/II ROS Generation Photoimmunotherapy by Molecular Engineering of Semiconducting Perylene Diimide

Efficient NIR-II Type-I AIE Photosensitizer for Mitochondria-Targeted Photodynamic Therapy through Synergistic Apoptosis-Ferroptosis

An Activatable Phototheranostic Probe for Anti‐hypoxic Type I Photodynamic‐ and Immuno‐Therapy of Cancer

Type I Photosensitizers Revitalizing Photodynamic Oncotherapy